Lixte Biotechnology Holdings, Inc. (LIXT) financial statements (2021 and earlier)

Company profile

Business Address 248 ROUTE 25A
EAST SETAUKET, NY 11733
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,0692,5994,2731,3062002544
Cash and cash equivalents5,0692,5994,2731,3062002544
Receivables 14     
Prepaid expense67 9    
Contract with customer, asset77  
Other undisclosed current assets15595262233573495
Total current assets:5,2282,6724,3341,368433598539
Noncurrent Assets
Prepaid expense  2    
Total noncurrent assets:  2    
TOTAL ASSETS:5,2282,6724,3371,368433598539
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:190144195312160159123
Interest and dividends payable     2 
Other undisclosed accounts payable and accrued liabilities190144195312160157123
Deferred revenue16 
Due to related parties      93
Other undisclosed current liabilities109416615912758
Total current liabilities:217238211373219286273
Noncurrent Liabilities
Total liabilities:217238211373219286273
Stockholders' equity
Stockholders' equity attributable to parent5,0122,4344,126995215312266
Preferred stock3,5003,5003,5003,5003,5001,750 
Common stock1776555
Additional paid in capital31,86426,01625,26820,00517,41717,13015,979
Accumulated deficit(30,354)(27,089)(24,649)(22,515)(20,707)(18,572)(15,718)
Total stockholders' equity:5,0122,4344,126995215312266
TOTAL LIABILITIES AND EQUITY:5,2282,6724,3371,368433598539

Income statement (P&L) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues
(Revenue, Net)
     200 
Cost of revenue
(Cost of Goods and Services Sold)
    (25)(53)(25)
Gross profit:    (25)147(25)
Operating expenses(3,266)(2,490)(2,138)(1,810)(2,135)(2,846)(2,403)
Other undisclosed operating income    255325
Operating loss:(3,266)(2,490)(2,138)(1,810)(2,135)(2,646)(2,403)
Nonoperating income
(Investment Income, Nonoperating)
55051000
Interest and debt expense(4)      
Net loss:(3,265)(2,440)(2,133)(1,808)(2,135)(2,646)(2,403)
Other undisclosed net loss attributable to parent     (206)(363)
Net loss attributable to parent:(3,265)(2,440)(2,133)(1,808)(2,135)(2,852)(2,766)
Other undisclosed net loss available to common stockholders, basic     (2) 
Net loss available to common stockholders, diluted:(3,265)(2,440)(2,133)(1,808)(2,135)(2,854)(2,766)

Comprehensive Income ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(3,265)(2,440)(2,133)(1,808)(2,135)(2,646)(2,403)
Comprehensive loss, net of tax, attributable to parent:(3,265)(2,440)(2,133)(1,808)(2,135)(2,646)(2,403)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: